Eli Lilly and Co. will focus on developing biotech drugs for personalized treatment and expanding networks with other firms to accelerate drug development as the company faces patent expiration for its best-selling medicines, CEO John Lechleiter said in a speech. Lilly is also planning more job cuts and will not be seeking large-scale mergers or acquisitions, Lechleiter said.

Full Story:

Related Summaries